Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

This potential ban is being challenged by TikTok on First Amendment grounds, with the company referring to it as an ...

These 173 leaders will help steer the firm as Wall Street readies for a potential flood of dealmaking, from M&A to IPOs.

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 ...

Wall Street’s largest investment banks are looking to award traders and dealmakers with their largest bonus increases since the pandemic, with ...

The performance of Morgan Stanley’s MS trading business (constituting a significant portion of its top line) is expected to ...

Global equity issuance rose 20% last year, but stock market launches have so far lagged that increase, remaining far below ...

British equities slipped on Friday, with financial sectors such as insurance and lenders leading losses ahead of the U.S.

Andrew Forrest has taken a ‘bring it on’ stance in response to ExxonMobil’s defamation lawsuit, which it has filed against ...

BlackRock's pro-risk stance in early 2025 would favor an overweight to equities in a traditional portfolio comprising 60% stocks and 40% bonds, said Kristy Akullian, the giant asset manager's head of ...

Morgan Stanley is a buy on weakness with strong dividend growth and projected revenue growth in Q4 2024 and early 2025. Click for our MS earnings preview.